Physician profile
Rami Jambeih
NPI 1538397245
$5,827.14
in general payments reported to CMS, 2019-2025
38 companies · $1,526 in 2025
The $1,526 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $616 · 2020: $697 · 2021: $515 · 2022: $688 · 2023: $930 · 2024: $854 · 2025: $1,526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,105 · Education: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,104.54 |
| Education | $205.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $835.99 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $532.47 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Harmony Biosciences LLC | $428.83 | 2020-2025 | Wakix |
| Astrazeneca Pharmaceuticals Lp | $377.54 | 2019-2025 | Airsupra, Tezspire, Fasenra |
| Pfizer INC. | $367.48 | 2019-2025 | |
| Jazz Pharmaceuticals INC. | $336.24 | 2020-2025 | |
| Regeneron Healthcare Solutions, INC. | $322.64 | 2023-2025 | Dupixent |
| Insmed, INC. | $304.72 | 2020-2025 | Arikayce, Brinsupri |
| Mylan Specialty L.P. | $242.57 | 2019-2024 | Yupelri |
| Axsome Therapeutics, INC. | $195.75 | 2023-2025 | Sunosi |
| Actelion Pharmaceuticals US, INC. | $193.87 | 2020-2025 | Uptravi, Opsumit |
| Genentech USA, INC. | $187.12 | 2019-2023 | Xolair |
| Grifols USA, LLC | $184.40 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $180.32 | 2025 | |
| Amgen INC. | $173.38 | 2022-2025 | Tezspire, Tavneos |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $121.86 | 2023-2025 | Winrevair, Zerbaxa, Recarbrio |
| Philips North America LLC | $101.72 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $94.31 | 2020-2023 | Airduo Digihaler |
| Csl Behring | $82.21 | 2021-2025 | Kcentra |
| Takeda Pharmaceuticals U.S.A., INC. | $74.18 | 2020-2021 | |
| Viatris Specialty LLC | $71.10 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $49.68 | 2019 | |
| United Therapeutics Corporation | $46.75 | 2022-2023 | Tyvaso |
| Janssen Pharmaceuticals, INC | $43.98 | 2022-2023 | Xarelto |
| Electromed, INC. | $36.50 | 2021-2024 | Smartvest |
| Chiesi USA, INC. | $36.24 | 2020-2024 | Cleviprex |
| E.R. Squibb & Sons, L.L.C. | $29.14 | 2023 | Camzyos, Eliquis |
| Abbott Laboratories | $20.87 | 2022 | |
| Sanofi-Aventis U.S. LLC | $19.50 | 2021 | |
| Verona Pharma, INC. | $18.88 | 2025 | Ohtuvayre |
| Bayer Healthcare Pharmaceuticals INC. | $17.16 | 2022 | |
| Abbvie INC. | $16.26 | 2022 | |
| Circassia INC. | $15.03 | 2019 | |
| Resmed Corp | $14.90 | 2022 | |
| Ambu INC. | $14.64 | 2023 | |
| Allergan, INC. | $14.30 | 2020 | |
| Paratek Pharmaceuticals, INC. | $14.09 | 2022 | |
| Inogen, INC. | $10.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rami Jambeih listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.